ProductUpdated on 10 September 2024
PREBIOTIC COMPOSITION OF ESSENTIAL OILS AND L-CARNITINE
Technology Transfer Manager - Specialist on Intellectual Property at Universidad de Málaga
Málaga, Spain
About
Ischemic heart disease (ICD) and type 2 diabetes mellitus (T2DM) are currently problematic health conditions worldwide. These diseases are closely related due to the association between metabolic state and cardiovascular risk. Previous studies on both diseases suggest the relationship between the intestinal microbiota and these pathologies. The consumption of the Mediterranean diet has anti-inflammatory and antioxidant properties. In addition, it has been related to an increase in beneficial bacteria, such as those related to the production of short-chain fatty acids of great importance for health. However, it has been observed that these beneficial effects are limited, which is why it is necessary to design new nutritional strategies, such as the development of nutraceuticals. For this reason, a research group has developed a composition of essential oils from plants typical of the Mediterranean diet together with L-carnitine. One of the examples of the effect of these nutraceutical formulas on the microbiota is the reduction of proatherogenic substances of bacterial origin, such as TMAO, which are associated with the development of cardiovascular diseases. These formulas based on essential oils present, in addition to the beneficial effects typical of the Mediterranean diet, those specific to cardiometabolic diseases such as IC and DMT2.
Advantages
• Allows a prebiotic improvement on the intestinal microbiota in relation to IC and DMT2. • It has beneficial effects on IC and DMT2 due to its anti-inflammatory and antioxidant activity.
Uses and Applications
The application of the invention is in the medical field, specifically in heart disease. At present, the prediction of the progression of these diseases and their relationship with intestinal microbiota is increasingly important. The present invention solves this problem, since it allows the development of new nutraceutical formulas that reduce proaterogenic substances of bacterial origin, such as TMAO, which are associated with the development of cardiovascular diseases.
Looking for
- Other
Applies to
- Pharmaceutical industry
- Health innovation
Similar opportunities
Product
NEW TREATMENT FOR PARKINSON'S DISEASE
- Other
- Health innovation
- Pharmaceutical industry
Ana Somé
Technology Transfer Manager - Specialist on Intellectual Property at Universidad de Málaga
Málaga, Spain
Product
- Cosmetic industry
- Health innovation
- Distribution Partner
- Pharmaceutical industry
OLIVIER DECAZES
Founder at L'OFFICINE DU MONDE / SAS ODELIA
Montigny-le-Bretonneux, France
Expertise
Treatments against rare dermatological diseases (Ref. UC3M_172)
ALBERTO DÍAZ BERMEJO
Universidad Carlos III de Madrid
Madrid, Spain